Am. J. Respir. Crit. Care Med., Volume 160, Number 3, September 1999, 866-872

Effect of Clarithromycin Regimen for Mycobacterium avium Complex Pulmonary Disease

EISAKU TANAKA, TERUMI KIMOTO, KAZUNARI TSUYUGUCHI, ISAO WATANABE, HISAKO MATSUMOTO, AKIO NIIMI, KATSUHIRO SUZUKI, TAKAKO MURAYAMA, RYOICHI AMITANI, and FUMIYUKI KUZE

Department of Infectious Diseases, Faculty of Medicine, Kyoto University, Kyoto, Japan

We have investigated the efficacy of a clarithromycin-containing four-drug regimen for Mycobacterium avium complex (MAC) pulmonary disease in 46 patients without acquired immunodeficiency syndrome (AIDS). The patients were 14 males and 32 females with a mean age of 60.9 ± 11.5 yr. Patients received 10 mg/kg/d of clarithromycin plus ethambutol, rifampin, and initial kanamycin and subsequent quinolone for 24 mo. Seven patients (15.2%) were dropped in the first 6 mo. Among 39 patients who received more than 6 mo of therapy, 28 patients (71.8%) converted their sputa to negative: 26 of 31 patients (83.9%) infected with clarithromycin-susceptible strains and two of eight patients (25.0%) with resistant or intermediate strains. The timing of sputum conversion was 3.6 ± 1.9 mo, with a range of 2 to 9 mo. The conversion rate was significantly lower in patients who were infected with clarithromycin-resistant or intermediate strains, who had had prior therapy (55.0% versus 89.5%), or who were acid-fast bacilli (AFB) smear-positive at entry (60.7% versus 100%). The age and sex of patients, the species of pathogen (M. avium or M. intracellulare), type and extent of the disease, and the use of kanamycin did not significantly affect the conversion rate. Although the regimen was efficacious for newly treated patients, frequent adverse reactions and a low conversion rate of sputum in retreated patients are problems that remain to be solved.

This article has been cited by other articles:

				S. Kuroishi, Y. Nakamura, H. Hayakawa, M. Shirai, Y. Nakano, K. Yasuda, T. Suda, H. Nakamura, and K. Chida Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings Eur. Respir. J., July 1, 2008; 32(1): 147 - 152. [Abstract] [Full Text] [PDF]

				P A Jenkins, I A Campbell, J Banks, C M Gelder, R J Prescott, and A P Smith Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy Thorax, July 1, 2008; 63(7): 627 - 634. [Abstract] [Full Text] [PDF]

				D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]

				M. Watanabe, N. Hasegawa, A. Ishizaka, K. Asakura, Y. Izumi, K. Eguchi, M. Kawamura, H. Horinouchi, and K. Kobayashi Early Pulmonary Resection for Mycobacterium Avium Complex Lung Disease Treated With Macrolides and Quinolones Ann. Thorac. Surg., June 1, 2006; 81(6): 2026 - 2030. [Abstract] [Full Text] [PDF]

				S. K. Field and R. L. Cowie Lung Disease Due to the More Common Nontuberculous Mycobacteria Chest, June 1, 2006; 129(6): 1653 - 1672. [Abstract] [Full Text] [PDF]

				P. K. Lam, D. E. Griffith, T. R. Aksamit, S. J. Ruoss, S. M. Garay, C. L. Daley, and A. Catanzaro Factors Related to Response to Intermittent Treatment of Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1283 - 1289. [Abstract] [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, S. Shepherd, J. McLarty, L. Griffith, and R. J. Wallace Jr. Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 250 - 253. [Abstract] [Full Text] [PDF]

				S. K. Field, D. Fisher, and R. L. Cowie Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection Chest, August 1, 2004; 126(2): 566 - 581. [Abstract] [Full Text] [PDF]

				S. K. Field and R. L. Cowie Treatment of Mycobacterium avium-intracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine Chest, October 1, 2003; 124(4): 1482 - 1486. [Abstract] [Full Text] [PDF]

				K. N. Olivier, D. J. Weber, R. J. Wallace Jr., A. R. Faiz, J.-H. Lee, Y. Zhang, B. A. Brown-Elliot, A. Handler, R. W. Wilson, M. S. Schechter, et al. Nontuberculous Mycobacteria: I: Multicenter Prevalence Study in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 828 - 834. [Abstract] [Full Text] [PDF]

				Y. Shiraishi, Y. Nakajima, K. Takasuna, T. Hanaoka, N. Katsuragi, and H. Konno Surgery for Mycobacterium avium complex lung disease in the clarithromycin era Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 314 - 318. [Abstract] [Full Text] [PDF]

				Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol Thorax, March 1, 2001; 56(3): 167 - 172. [Abstract] [Full Text]